Compare AbbVie Inc (ABBV) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Merck & Co., Inc. — how do they compare? AbbVie Inc trades at $249.34 (market cap $438.19B), while Merck & Co., Inc. trades at $132.24 (market cap $323.00B). The key difference: AbbVie Inc is the larger of the two by market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | MRK | |
|---|---|---|
Market Cap | $438.19B | $323.00B |
Sector | Health | Health |
52-Week High | $263.58 | $131.84 |
52-Week Low | $197.38 | $77.60 |
Enterprise Value | $502.45B | $369.77B |
Dividend Yield | 2.79% | 2.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.44, up 0.57% today, with a bullish technical signal and strong support near $243. The company reported revenue of $61.16B in 2025, with net income of $4.23B, and has beaten EPS estimates for three consecutive quarters. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying interest.
Outlook remains positive with a consensus price target of $281.33, though high P/E of 70.05 and looming patent cliffs in the 2030s present risks. Revenue growth is driven by Skyrizi and Rinvoq, offsetting Humira declines, supporting a buy-rated stance amid cautious optimism for sustained expansion.
Merck (MRK) trades at $130.49, up 1.49% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, signaling strategic growth initiatives.
The outlook for Merck is positive, supported by analyst consensus favoring a buy rating and a price target of $139.90, implying upside potential. Key risks include rising debt levels and competitive pressures in the pharma sector. Investors should weigh the company's robust cash flow and dividend payments against execution risks in M&A integration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
